Hide metadata

dc.date.accessioned2013-03-12T12:37:20Z
dc.date.available2013-03-12T12:37:20Z
dc.date.issued2007en_US
dc.date.submitted2007-10-29en_US
dc.identifier.citationSundrehagen, Bendik Holmsen. Diagnostikk og behandling av colorektale levermetastaser. Prosjektoppgave, University of Oslo, 2007en_US
dc.identifier.urihttp://hdl.handle.net/10852/29387
dc.description.abstractBackground: This paper reviews development of multidisciplinary modalities and the aggressive surgical approach that has been adopted to extend the frontiers of surgical therapy for colorectal metastases. The review is restricted to seven specific topics: 1) patient selection, 2) timing of resection of liver metastases synchronous to colorectal tumour, 3) re-resection when hepatic recurrence 4) prognostic factors for recurrence and survival after hepatectomy, 5) downstaging with neoadjuvant chemotherapy, 6) systemic adjuvant chemotherapy and 7) quality of life Methods: A PubMed, Embase and Cochrane search was performed to identify papers regarding treatment of colorectal liver metastases. Results/conclusion: All patients investigated for surgical treatment of colorectal liver metastases should undergo a spiral CT, in addition to IOUS, before resection. CT-PET or FDG-PET can be used if spiral CT is inconclusive. Biopsy should not be a part of the preoperative assessments. Patients with liver metastases synchronous to colorectal tumour should be treated with a staged resection if the patient is over 70 years old, needs an extensive hepatectomy or has a significant blodloss during the colectomy. All other patients should be treated with simultan resection. Patients with hepatic recurrence after hepatectomy, should be treated with re-resection if possible. Patients with resectable hepatic metastases should be treated with a curative hepatectomy regardless of prognostic factors. 20-45 % of non-resectable pre-selected patients, can become resectable, if downstaged with neoadjuvant chemotherapy. These patients have a significant longer survival than patients treated only with palliative chemotherapy, but a high recurrence rate. All patients should receive systemic adjuvant chemotherapy, because of a significant longer diseases-free survival. A more aggressive surgical approach does not influence on “quality-of-life”, but unnecessary laprotomy must be avoided.nor
dc.language.isonoben_US
dc.subjectkirurgi
dc.titleDiagnostikk og behandling av colorektale levermetastaser : Hvem skal behandles og hva er behandlingsalternativene?en_US
dc.typeMaster thesisen_US
dc.date.updated2008-02-27en_US
dc.creator.authorSundrehagen, Bendik Holmsenen_US
dc.subject.nsiVDP::780en_US
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&rft.au=Sundrehagen, Bendik Holmsen&rft.title=Diagnostikk og behandling av colorektale levermetastaser&rft.inst=University of Oslo&rft.date=2007&rft.degree=Prosjektoppgaveen_US
dc.identifier.urnURN:NBN:no-17801en_US
dc.type.documentProsjektoppgaveen_US
dc.identifier.duo66869en_US
dc.contributor.supervisorProfessor dr.med. Trond Buanesen_US
dc.identifier.bibsys080319912en_US
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/29387/3/ProsjektSundrehagen.pdf


Files in this item

Appears in the following Collection

Hide metadata